Loading...
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors improve outcomes in heart failure with reduced ejection fraction (HFrEF). But how much benefit can patients anticipate over a lifetime of drug therapy?
Investigators used data from a large, randomized trial of dapagliflozin for HFrEF to project long-term effects of treatment over the patient's lifetime by extrapolating mean event-free survival from a primary endpoint (unplanned hospitalization for heart failure, urgent heart failure visit requiring intravenous therapy, or cardiovascular death) as well as overall survival. For example, for a 65-year-old man, estimated event-free survival was 2.1 years longer with dapagliflozin than with placebo (8.3 years vs. 6.2 years) and overall survival w…